|
Market Closed -
Nasdaq
16:00:00 2026-09-15 EDT
|
5-day change | 1st Jan Change | ||
| 4.810 USD | -1.43% |
|
-7.68% | -25.54% |
| 08-12 | Aquestive Therapeutics, Inc., Q2 2026 Earnings Call, Aug 12, 2026 | |
| 08-11 | Aquestive Therapeutics Q2 Loss Widens, Revenue Rises | MT |
Company Valuation: Aquestive Therapeutics, Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 156.2 | 48.85 | 134.9 | 324.6 | 788.1 | 603.7 | - | - |
| Change | - | -68.73% | 176.07% | 140.67% | 142.81% | -23.4% | - | - |
| Enterprise Value (EV) 1 | 179.8 | 73.73 | 138.5 | 285.6 | 704.5 | 525.7 | 603.7 | 603.7 |
| Change | - | -58.99% | 87.89% | 106.15% | 146.69% | -25.38% | 14.84% | 0% |
| P/E | -2.1x | -0.81x | -15.5x | -6.98x | -8.28x | -9.43x | -10x | -10.2x |
| PBR | - | - | - | - | - | - | - | - |
| PEG | - | 0x | 0.2x | -0x | -0.2x | 0.3x | 1.7x | 4.9x |
| Capitalization / Revenue | 3.07x | 1.02x | 2.67x | 5.64x | 17.7x | 12.1x | 8.91x | 5.66x |
| EV / Revenue | 3.54x | 1.55x | 2.74x | 4.96x | 15.8x | 10.5x | 8.91x | 5.66x |
| EV / EBITDA | -5.67x | -2.09x | -12x | -12.4x | -11.2x | -17.4x | -15.7x | -81.6x |
| EV / EBIT | -5.18x | -1.75x | -9.17x | -9.28x | -9.92x | -13.1x | -10.6x | -13.7x |
| EV / FCF | - | - | - | - | - | - | - | - |
| FCF Yield | - | - | - | - | - | - | - | - |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | -1.85 | -1.12 | -0.13 | -0.51 | -0.78 | -0.51 | -0.48 | -0.47 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | 50.83 | 47.68 | 50.58 | 57.56 | 44.54 | 49.93 | 67.77 | 106.7 |
| EBITDA 1 | -31.72 | -35.3 | -11.56 | -22.95 | -62.88 | -30.28 | -38.41 | -7.4 |
| EBIT 1 | -34.68 | -42.07 | -15.1 | -30.77 | -71.05 | -40.25 | -57.12 | -43.97 |
| Net income 1 | -70.54 | -54.41 | -7.87 | -44.14 | -83.78 | -63.62 | -60.23 | -62.8 |
| Net Debt 1 | 23.53 | 24.88 | 3.658 | -39.02 | -83.66 | -78 | - | - |
| Reference price 2 | 3.890 | 0.902 | 2.020 | 3.560 | 6.460 | 4.810 | 4.810 | 4.810 |
| Nbr of stocks (in thousands) | 40,164 | 54,156 | 66,767 | 91,178 | 122,003 | 125,512 | - | - |
| Announcement Date | 3/8/22 | 3/7/23 | 3/5/24 | 3/5/25 | 3/4/26 | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -9.43x | 10.53x | -17.36x | - | 604M | |
| 32.3x | 11.75x | 23.82x | 0.61% | 1,013B | |
| 29.72x | 6.61x | 18.51x | 2.01% | 644B | |
| 33.26x | 7.79x | 16.1x | 2.61% | 465B | |
| 19.53x | 4.77x | 11.83x | 2.78% | 352B | |
| 19.64x | 5.13x | 12.73x | 3.13% | 264B | |
| 20.94x | 4.32x | 12.33x | 2.04% | 253B | |
| 23.76x | 6.28x | 11.19x | 2.69% | 203B | |
| 12.28x | 4.47x | 9.35x | 4.09% | 188B | |
| -44.25x | 6.45x | 25.21x | 2.25% | 181B | |
| Average | 13.78x | 6.81x | 12.37x | 2.47% | 356.43B | |
| Weighted average by Cap. | 23.51x | 7.63x | 17.61x | 2.01% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- AQST Stock
- Valuation Aquestive Therapeutics, Inc.
Select your edition
All financial news and data tailored to specific country editions
